EAGLE PHARMACEUTICALS, INC.
EAGLE PHARMACEUTICALS, INC. is grouped at the issuer level across 1 linked ticker lifecycle, combining public listing, delisting, source, and shareholder outcome records from the archive.
Lifecycle Map
Issuer enters the archive
Dec 20, 2013EAGLE PHARMACEUTICALS, INC. is represented as an issuer-level entity with 1 linked public-market ticker lifecycle.
Delisting event
Nov 26, 2024Removed from listing - SEC Form 25 filed.
SourceEGRX stopped trading
Nov 26, 2024EGRX is linked to EAGLE PHARMACEUTICALS, INC. and ended with final status "delisted".
Source
Entity Graph
EAGLE PHARMACEUTICALS, INC.issuedEGRX
EGRXlisted onNASDAQ
EGRXresulted inunknown
Source-Backed Claims
- On December 2, 2024, Eagle Pharmaceuticals, Inc. entered into Amendment No. 1 to the Rights Agreement with Equiniti Trust Company, LLC.8-K
- The Amendment to the Rights Agreement includes certain technical amendments concerning the rights of the Company's Board of Directors.8-K
- The Rights Agreement remains unmodified and in full force and effect according to its terms after the amendment.8-K
- Eagle Pharmaceuticals' Common Stock was suspended from trading on Nasdaq effective October 3, 2024, and began trading on the OTC Expert Market on October 4, 2024.8-K
- Eagle Pharmaceuticals received a notice from Nasdaq on October 1, 2024, indicating its decision to delist the Company's Common Stock.8-K
Associated Tickers
Public-market security lifecycles tied to this issuer record.